<DOC>
	<DOCNO>NCT02634437</DOCNO>
	<brief_summary>This study design observe effect renal function pharmacokinetic , safety , tolerability profile Ulipristal acetate follow administration single oral dose 10 mg Ulipristal acetate tablet .</brief_summary>
	<brief_title>Study Ulipristal Acetate Female Patients With Moderately Severely Impaired Renal Function , Compared With Matched Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion Criteria Patients Renal Impairment : Have negative result serum pregnancy test screen negative result serum urine pregnancy test Day 1 If premenopausal , regular menstrual cycle ( cycle 2435 day duration ) past 6 month report patient If female childbearing potential , agree use effective method contraception ( i.e. , condom plus diaphragm spermicide , condom spermicide , nonhormonal intrauterine device ) become pregnant throughout study . Subjects least 2years postmenopausal ( support documentation obstetrician/gynecologist ) tubal ligation hysterectomy consider childbearing potential Be nonsmoking ( never smoke smoke within previous 6 month ) light smoker ( few 10 cigarette per day within previous 3 month ) For Patients Renal Impairment , medical history , physical examination , laboratory , test result consistent degree renal impairment , determine Investigator For Patients Normal Renal Function , state general good health base medical history routine physical examination match age weight renal dysfunction patient ( mean group difference Â±10 year age &lt; 20 % weight ) Known hypersensitivity Ulipristal Acetate ( UPA ) selective progesterone receptor modulators For Patients Renal Impairment , clinically significant disease state , opinion examine physician , body system ( renal function impairment ) For Patients Normal Renal Function , clinically significant disease state , opinion examine physician , body system Positive test result antihuman immunodeficiency virus type 1 , hepatitis B surface antigen , antihepatitis C virus screen Abnormal clinically significant result physical examination , medical history , serum chemistry , hematology , urinalysis History alcohol substance abuse within previous 5 year Positive test result benzoylecgonine ( cocaine ) , methadone , barbiturate , amphetamine , benzodiazepine , alcohol , cannabinoids , opiate , phencyclidine screen Day 1 . Patients Renal Impairment many enrol positive test result due prescription drug use approve Principal Investigator Sponsor Study Physician , casebycase basis Participation clinical investigation use experimental drug require repeat blood plasma draw within 30 day IP administration Participation blood plasma donation program within 60 30 day , respectively , Investigational Product ( IP ) administration Previously participate investigational study Ulipristal Acetate Breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>